Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 7, 1999, Pages 1747-1753

  Climo, Michael W ^a,b,c   Patron, Roberto L ^a   Archer, Gordon L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Neurology Service   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; GLYCOPEPTIDE; METICILLIN; NAFCILLIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AORTA VALVE DISEASE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; CONTROLLED STUDY; DIFFUSION; DILUTION; DRUG POTENTIATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS;

EID: 0032779486     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.7.1747     Document Type: Article

References (34)

1. Archer, G. L., and M. W. Climo. 1994. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob. Agents Chemother. 38:2231-2237.
2. Barr, J. G., E. T. Smyth, and G. M. Hogg. 1990. In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis. Eur. J. Clin. Microbiol. Infect. Dis. 9.-804-809.
3. Billot-Klein, D., L. Gutmann, D. Bryant, D. Bell, J. van Heijenoort, J. Grewal, and D. M. Shlaes. 1996. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics. J. Bacteriol. 178:4696-4703.
4. Boyce, J. M., and A. A. Medeiros. 1997. Clinical isolates of methicillin-resistant Staphylococcus aureus from the United States with subpopulations of cells with reduced susceptibility to vancomycin, abstr. LB-15, p. 6. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Centers for Disease Control and Prevention. 1997. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid. Mortal. Weekly Rep. 46:813-815.
6. Chambers, H. F., C. J. Hackbarth, T. A. Drake, M. G. Rusnak, and M. A. Sande. 1984. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to β-lactam antibiotics in vivo and in vitro. J. Infect. Dis. 149:894-903.
7. Climo, M. W., S. M. Markowitz, D. S. Williams, C. G. Hale-Cooper, and G. L. Archer. 1997. Comparison of in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species. J. Antimicrob. Chemother. 40:59-66.
8. Climo, M. W., R. L. Patron, B. P. Goldstein, and G. L. Archer. 1998. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 42:1355-1360.
9. Daum, R. S., S. Gupta, R. Sabbagh, and W. M. Milewski. 1992. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomcyin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J. Infect. Dis. 166:1066-1072.
10. De Jonge, B. L., and A. Tomasz. 1993. Abnormal peptidoglycan produced in a methicillin-resistant strain of Staphylococcus aureus grown in the presence of methicillin: functional role for penicillin-binding protein 2a in cell wall synthesis. Antimicrob. Agents Chemother. 37:342-346.
11. De Jonge, B. L. M., Y.-S. Chang, D. Gage, and A. Tomasz. 1992. Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain. The role of penicillin binding protein 2a. J. Biol. Chem. 267:11248-11254.
12. Domaracki, B. E., A. Evans, K. E. Preston, H. Fraimov, and R. A. Venezia. 1998. Increased oxacillin activity associated with glycopeptides in coagulase-negative staphylococci. Eur. J. Clin. Microbiol. Infect. Dis. 17:143-150.
13. Gopal, V., A. L. Bisno, and F. J. Silverblatt. 1976. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. JAMA 236:1604-1606.
14. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguru, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-146.
15. Levine, D. P., B. S. Fromm, and B. R. Reddy. 1991. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115:674-680.
16. Lowdin, E., I. Odenholt, and O. Cars. 1998. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 42:2739-2744.
17. Mainardi, J.-L., D. M. Shlaes, R. V. Goering, J. H. Shlaes, J. F. Acar, and F. W. Goldstein. 1995. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J. Infect. Dis. 171:1646-1650.
18. Moreira, B., S. Boyle-Vavra, B. L. M. de Jonge, and R. S. Daum. 1997. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1788-1793.
19. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A4, 4th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk susceptibility tests, 6th ed. Approved standard M7-A6 (M100-S7). National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Perlman, B. B., and L. R. Freedman. 1971. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J. Biol. Med. 44:206-213.
22. Ploy, M. C., C. Grelaud, C. Martin, L. de Lumley, and F. Denis. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212.
23. Portier, H., A. Kazmierczak, F. Lucht, J. C. Tremeaux, P. Chavanet, and J. M. Duez. 1985. Cefotaxime in combinations with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection 13:S123-S128.
24. Robinson-Dunn, B., G. Jennings, J. Mitchell, M. Ionescu, D. Farnaz, S. Donabedian, M. B. Perri, L. A. Thal, J. Sunstrum, J. W. Chow, T. Smith, and M. J. Zervos. 1997. Characterization of a unique isolate of vancomycin-intermediate Staphylococcus aureus, abstr. LB-14, p. 6. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
25. Schwalbe, R. S. W. J. Ritz, P. R. Verma, E. A. Barranco, and P. H. Gilligan. 1987. Emergence of vancomycin resistance in Staphylococcus haemolyticus. J. Infect. Dis. 161:45-51.
26. Shlaes, D. M., J. H. Shlaes, S. Vincent, L. Etter, P. D. Fey, and R. V. Goering. 1993. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrob. Agents Chemother. 37:2432-2437.
27. Sieradzki, K., P. Villari, and A. Tomasz. 1998. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 42:100-107.
28. Sieradzki, K., and A. Tomasz. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557-2566.
29. Sieradzki, K., and A. Tomasz. 1998. Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis. Microb. Drug Resist. 4:159-168.
30. Sieradzki, K., and A. Tomasz. 1997. Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J. Antimicrob. Chemother. 39(Suppl. A):47-51.
31. Simon, C., and M. Simon. 1991. In vitro activity of flomoxef and cefazolin in combination with vancomycin. Infection 19(Suppl. 5):S276-S278.
32. Small, P. M., and H. F. Chambers. 1990. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34:1227-1231.
33. Smith, T. L., M. Pearson, K. Wilcox, B. Robinson-Dunn, B. Hill, M. Lancaster, G. Rodgers, C. Ruble, E. Flegel, S. McCallister, J. M. Miller, H. Ellis, C. Campbell, and W. R. Jarvis. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997. abstr. LB-16, p. 6. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
34. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopcptides. J. Clin. Microbiol. 36:1020-1027.